Swedbank AB Has $24.44 Million Position in Insulet Corporation $PODD

Swedbank AB increased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 11.0% during the fourth quarter, Holdings Channel reports. The fund owned 85,988 shares of the medical instruments supplier’s stock after acquiring an additional 8,500 shares during the quarter. Swedbank AB’s holdings in Insulet were worth $24,441,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Insulet during the 4th quarter worth approximately $28,000. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 43 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet during the 2nd quarter worth approximately $51,000.

Insulet Stock Performance

NASDAQ:PODD opened at $154.87 on Tuesday. The stock has a fifty day moving average price of $189.91 and a 200-day moving average price of $249.64. The company has a market cap of $10.73 billion, a price-to-earnings ratio of 36.02, a PEG ratio of 1.22 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a fifty-two week low of $145.59 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts anticipate that Insulet Corporation will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. Jefferies Financial Group decreased their target price on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. The Goldman Sachs Group set a $237.00 price objective on Insulet in a report on Thursday, May 7th. Piper Sandler decreased their price objective on Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. BTIG Research decreased their price objective on Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Raymond James Financial decreased their price objective on Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $254.96.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.